{
    "pmcid": "10865538",
    "qa_pairs": {
        "How does AlphaFold-Multimer contribute to the design of nanobody binders against SARS-CoV-2?": [
            "By predicting protein-protein interactions and multimeric structures",
            "By synthesizing new nanobody sequences",
            "By conducting high-throughput screening of nanobody libraries",
            "By performing in vivo testing of nanobody efficacy"
        ],
        "What is one of the challenges associated with using synthetic libraries for sdAb development?": [
            "Protein folding stability and solubility",
            "Limited availability of synthetic phage libraries",
            "High cost of synthetic library construction",
            "Inability to target viral proteins"
        ],
        "What is the primary target of the single-domain antibodies developed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What is the purpose of the focused library (sdAb-RBD) in the two-stage phage screening strategy?": [
            "To enrich for RBD-specific binders with randomized CDR3 regions",
            "To identify binders with high solubility and stability",
            "To screen for binders against multiple SARS-CoV-2 proteins",
            "To validate the initial binders through molecular dynamics simulations"
        ],
        "Which single-domain antibody was identified as having the ability to compete with ACE2 for RBD binding?": [
            "sdAb39",
            "sdAb21",
            "sdAb57",
            "sdAb12"
        ]
    }
}